Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/11/20
Catalyst Biosciences Receives Patent in the European Union for Its Factor IX PortfolioGlobeNewsWire • 04/28/20
Catalyst Biosciences Completes Phase 2b Trial of Subcutaneous Factor IX Dalcinonacog Alfa (DalcA)GlobeNewsWire • 04/21/20
Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD CongressGlobeNewsWire • 01/27/20
Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of DirectorsGlobeNewsWire • 01/17/20